Hepatitis C–associated glomerulonephritis

Hepatitis C–associated glomerulonephritis is a renal expression of the systemic disease caused by Hepatitis C virus infection. Its decisive clinical importance lies in the way an infection commonly discussed as a liver disorder can produce immune-mediated injury in native and transplanted kidneys, while the kidney disease itself may require treatment even when hepatic injury alone would not justify antiviral therapy.

Definition and Clinical Spectrum

Hepatitis C–associated glomerulonephritis occurs in the setting of active infection: patients with HCV-associated glomerular disease are generally positive for HCV RNA in serum, and chronic infection is established by the combined presence of anti-HCV antibodies and detectable HCV RNA. The principal renal lesion is type I membranoproliferative glomerulonephritis associated with type II mixed cryoglobulinemia. Non-cryoglobulinemic membranoproliferative glomerulonephritis and membranous glomerulonephritis are described less often.

The clinical presentation is dominated by proteinuria and microscopic hematuria, with or without impaired kidney function. Patients may develop nephrotic or non-nephrotic proteinuria, reduced estimated glomerular filtration rate, and variable renal dysfunction. International guidance recommends that people with Hepatitis C virus infection undergo at least annual assessment for proteinuria, hematuria, and estimated glomerular filtration rate, with kidney biopsy considered when clinical evidence suggests glomerulonephritis. Early recognition is important because timely therapy may improve renal outcomes.

Epidemiology and Association with Chronic Kidney Disease

The association is not confined to patients with advanced liver disease. HCV-infected patients, including those with kidney or liver transplants, have an increased risk of glomerular lesions leading to chronic kidney disease, and such lesions have been reported both with and without significant hepatic disease. In case series of membranoproliferative glomerulonephritis, HCV seropositivity was approximately ten times more prevalent than in HCV-negative patients.

Broader epidemiological studies reinforce the association. In a United States study of 18,002 patients with HCV infection and 25,137 controls whose baseline estimated glomerular filtration rate exceeded 60 ml/min/1.73 m2, HCV infection was associated with a higher risk of developing chronic kidney disease stages 3–5. Older age, hypertension, and diabetes increased risk in both groups, while decompensated liver disease strongly predicted chronic kidney disease. HCV-infected patients nevertheless reached chronic kidney disease in a shorter time.

A separate comparison of 552 anti-HCV-positive patients with 313 HCV-negative patients found chronic kidney disease in 9.6% and 5.1%, respectively. The HCV-positive group also progressed more quickly to chronic kidney disease and end-stage renal disease, and a higher baseline viral load independently predicted chronic kidney disease. Other data show an association particularly with albuminuria or proteinuria: among individuals aged 60 years or older in the NHANES III analysis, albuminuria affected 46% of HCV-positive individuals compared with 24% of those without HCV antibodies. In a Taiwanese study of non-diabetic patients, proteinuria occurred in 8.3% of anti-HCV-positive participants versus 5.1% of the seronegative group.

The magnitude of the renal complication varies geographically and by population. In 320 predialysis patients in Italy, HCV infection occurred in 6.25%, above the expected European range of 0.2–3.5%. By contrast, a prospective Norwegian cohort of 1,010 HCV-positive patients diagnosed between 1990 and 2000 found renal failure caused by membranoproliferative glomerulonephritis in 0.2%. Together, these findings identify HCV infection as a risk factor for proteinuria and impaired renal function without implying that every infected patient will develop overt glomerulonephritis.

Cryoglobulinemia and Pathogenesis

Hepatitis C virus infection is the major cause of mixed cryoglobulinemia, a systemic vasculitis that may involve the kidneys as well as the joints, skin, peripheral nerves, and blood vessels. Its manifestations include arthralgias or arthritis, Raynaud phenomena, purpura, peripheral neuropathy, hypocomplementemia, and kidney disease. Cryoglobulins are essential to the diagnosis, and HCV RNA is usually detectable in serum; rheumatoid factor may also be positive. Liver enzyme values can remain normal or only mildly elevated, so the absence of striking biochemical liver abnormalities does not exclude clinically important renal disease.

Renal involvement may appear as proteinuria, hematuria, reduced estimated glomerular filtration rate, acute nephritic syndrome, or nephrotic syndrome. Acute nephritic syndrome is reported as the presentation in about 25% of patients with mixed cryoglobulinemia, and nephrotic syndrome in about 20%. Purpura, arthralgias, or neuropathy may precede kidney disease by several years, giving the systemic illness a long lead-in before its renal consequences become apparent. HCV is mainly associated with type II mixed cryoglobulinemia, while cryoglobulinemic membranoproliferative glomerulonephritis is the characteristic renal lesion.

The central pathogenic model is immune-complex deposition in the glomeruli. In non-cryoglobulinemic membranoproliferative glomerulonephritis, deposits may contain HCV antigens and immunoglobulin G antibodies against HCV, resembling immune-complex injury described with hepatitis B virus. In membranous glomerulonephritis, immune complexes containing HCV proteins may deposit in the glomerular basement membrane, although the causal role of HCV remains unsettled because viral antigens have been detected inconsistently and complement or immune-complex findings may be absent. Toll-like receptor 3 has also been proposed as a pathogenic link between viral infection and glomerular inflammation.

Diagnosis and Treatment

Diagnosis requires separating exposure from active disease. Third-generation enzyme-linked immunosorbent assays detect anti-HCV antibodies, but antibodies alone cannot distinguish resolved infection from ongoing infection. Detectable HCV RNA in serum, measured with sensitive molecular assays whose threshold is around 15 IU/ml, identifies active infection. Evaluation of a patient with chronic HCV infection should address both hepatic injury and extrahepatic disease, including cryoglobulinemia-associated vasculitis and renal involvement.

The renal assessment begins with urinalysis and measurement of kidney function. Proteinuria, microscopic hematuria, and a falling estimated glomerular filtration rate should prompt consideration of HCV-associated glomerulonephritis, particularly when cryoglobulinemia or systemic vasculitic signs are present. Kidney biopsy can define the lesion and distinguish membranoproliferative glomerulonephritis from other causes of glomerular injury. Liver fibrosis may be assessed by biopsy or noninvasive methods such as FibroScan, allowing the hepatic and renal dimensions of the infection to be evaluated together.

Treatment depends on renal severity. For moderate renal disease, therapy may rely on anti-HCV treatment alone, traditionally a combination of standard or pegylated interferon-α and ribavirin. Recommendations described in the source support treatment for at least 48 weeks and continuation even when HCV RNA has not fallen by 2 log at week 12. Ribavirin dosing must be adjusted according to creatinine clearance to reduce the risk of hemolytic anemia.

Severe renal disease changes the therapeutic balance. Nephrotic syndrome, progressive renal failure, or disease refractory to antiviral therapy alone may require combined antiviral and immunosuppressive treatment, using cyclophosphamide or rituximab with corticosteroids. Angiotensin-converting enzyme inhibitors, with or without angiotensin-receptor blockers, are used as symptomatic therapy for proteinuric renal injury. The rationale is twofold: antiviral therapy addresses the persistent infectious stimulus, while immunosuppression may control the immune-mediated renal inflammation when kidney damage is immediately threatening.

Transplant and Health-System Significance

The disorder also occurs in renal and liver allografts. HCV-infected allograft recipients are prone to immune-complex-mediated glomerulonephritis much as non-transplanted patients are. HCV infection has been identified as a major risk factor for post-transplant proteinuria, and de novo membranoproliferative glomerulonephritis was first reported in HCV-infected renal allograft recipients in 1995. Later observations connected de novo disease with type II mixed cryoglobulinemia, although cryocrit levels in allograft recipients are often very low, usually below 5%, making cryoglobulin detection and characterization difficult.

HCV RNA may be much more concentrated in the cryocrit than in serum, supporting a pathogenic role for the virus in the cryoglobulinemia and suggesting activation of the classical complement pathway. Clinical findings in an HCV-related allograft lesion include hypertension, microscopic hematuria, proteinuria, and renal dysfunction, sometimes with nephrotic syndrome. Biopsy may show mesangial proliferation, double contours, and parietal IgM and C3 deposits. Electron microscopy can be necessary: membranoproliferative glomerulonephritis shows subendothelial electron-dense deposits, whereas transplant glomerulopathy shows radiolucent areas in the glomerular basement membrane. The two lesions can coexist, reflecting the combined harm of humoral immunity and autoimmunity.

The wider medical context makes prevention and early detection inseparable from treatment. HCV remains a major worldwide health problem, with an estimated prevalence near 3% of the global population and more than 170 million infected people in the period described. In hemodialysis, the risk of infection historically reflected both transfusion exposure and nosocomial transmission within dialysis units; molecular virology and phylogenetic analysis later demonstrated clusters of closely related viral isolates among patients treated in the same unit. For kidney-transplant candidates, screening is essential because as many as 25% of patients with active HCV infection may already have advanced liver fibrosis despite compensated disease. The renal lesion therefore belongs to a larger clinical system in which accurate RNA-based diagnosis, infection-control practice, liver staging, kidney surveillance, and timely antiviral therapy all determine whether a viral infection becomes permanent glomerular injury.